

IN THE CLAIMS:

Please Cancel claims 42 and 49-55 without prejudice.

Please substitute the following amended claims for the pending claims with the same number.

C³ 43. (Amended) A compound comprising an amino acid sequence selected from the group consisting of SEQ. ID. NO.:1, SEQ.ID.NO.:2, SEQ. ID. NO.:3, SEQ. ID. NO.:4, SEQ. ID. NO.:5, and SEQ. ID. NO.:7.

44. (Amended) A pharmaceutical composition comprising the compound of claim 43 and a biological agent.

45. (Amended) A pharmaceutical composition comprising the compound of claim 43 and a carrier.

46. (Amended) The compound of claim 43, wherein the compound further comprises a biological agent conjugated thereto.

47. (Amended) The compound of claim 43, wherein the compound further comprises a prodrug conjugated thereto.

48. (Amended) The compound of claim 43, wherein a therapeutic agent is conjugated thereto.

Please add the following new claims 56-59:

C4
56 (New) A modified peptide capable of specific binding with high affinity VEGF receptor comprising a mutation in an amino acid sequence of a compound of SEQ ID NO. 1, wherein the mutation is a substitution of one non-alanine amino acid residue with alanine.

57. (New) The modified peptide of claim 56 wherein said substitution occurs at an amino acid position selected from the group consisting of positions 1, 4, 5, 6, 7, 8, 9, 10, 12, 13, 15 and 16.

58. (New) The modified peptide of claim 57 wherein said substitution occurs at amino acid position 4, said modified peptide further comprising a second mutation in said amino acid sequence, said second mutation comprising a substitution of one non-alanine amino acid residue with alanine at position 6.

59. (New) The modified peptide of claim 57 wherein said substitution occurs at amino acid position 7, said modified peptide further comprising a second mutation in said amino acid sequence, said second mutation comprising a substitution of one non-alanine amino acid residue with alanine at position 10.